CABG Cabg Medical (MM)

CABG Medical Announces Initiation of CE Mark Clinical Trial MINNEAPOLIS, May 3 /PRNewswire-FirstCall/ -- CABG Medical, Inc. (NASDAQ:CABG) today announced the initiation of enrollment in its clinical trial for CE Mark approval of the Holly Graft(TM) System, a drug eluting graft (DEG) for facilitating a coronary artery bypass procedure. (Logo: http://www.newscom.com/cgi-bin/prnh/20050114/CGF013LOGO ) "The CE Mark is the designation for approval in major markets outside the United States and Japan," said Manny Villafana, Chairman and CEO. "We are excited to begin this important work with some of the most prominent cardiac surgery centers in the world." The first patient enrolled in the Holly Graft System clinical trial (second patient treated) was completed by Peter Tesar, M.D., and Trevor Fayers, M.D., Cardiac Surgeons at the Prince Charles Hospital in Brisbane, Australia. The surgeons in Australia also completed the first implant of the Holly Graft System in November 2004. Mr. Villafana continued, "We have worked closely with our scientific advisory board and our physician collaborators over the past four years in developing a technology that had a safety profile that was adequate to move into human evaluation. The incorporation of the Paclitaxel drug eluting technology into the Holly Graft System has made a profound difference that could positively impact the effectiveness of the device." CABG Medical management will be discussing the clinical status of the Holly Graft(TM) System as well as other topics at the Company's annual meeting, which will be held at the Minneapolis Club, 729 Second Avenue South, Minneapolis, Minnesota beginning at 3:30 p.m. (central daylight time) on Tuesday, May 3. All interested parties are encouraged to attend the meeting or to participate in a webcast through a link on the Company's website: http://www.cabgmedical.com/ or http://www.shareholder.com/cabg/MediaRegister.cfm?MediaID=15664 About CABG Medical CABG Medical, Inc. is a medical technology company developing technologies and therapies to improve the treatment of coronary heart disease by advancing conventional bypass surgery. We have designed our first product, the Holly Graft(TM) System, by leveraging our understanding of flow dynamics, material sciences and drug combinations to create a drug-eluting graft (DEG) system. Safe Harbor This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward looking statements as a result of a number of important factors, including regulatory actions, competition, and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission. http://www.newscom.com/cgi-bin/prnh/20050114/CGF013LOGO http://photoarchive.ap.org/ DATASOURCE: CABG Medical, Inc. CONTACT: Manny Villafana, Chairman & CEO, or John L. Babitt, President & COO, both of CABG Medical, Inc., +1-763-258-8005, FAX +1-763-258-8008 Web site: http://www.cabgmedical.com/

Copyright